Genmab As Stock Price, News & Analysis (OTCMKTS:GNMSF)

$176.40 -8.11 (-4.40 %)
(As of 02/21/2018 02:02 AM ET)
Previous Close$176.40
Today's Range$176.40 - $178.01
52-Week Range$163.00 - $239.75
Volume100 shs
Average Volume741 shs
Market Capitalization$11.29 billion
P/E Ratio63.84
Dividend YieldN/A
BetaN/A

About Genmab As (OTCMKTS:GNMSF)

Genmab As logoGenmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer in Denmark and internationally. The company markets Arzerra, a human monoclonal antibody for the treatment of chronic lymphocytic leukemia (CCL); and DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM). Its products under development include Ofatumumab to treat CLL and follicular lymphoma; Ofatumumab (OMB157) for relapsing remitting multiple sclerosis; and Daratumumab to treat MM, Non-Hodgkin's lymphoma, and solid tumors, as well as natural killer/T-cell lymphoma, nasal type. The company’s products under development also comprise Tisotumab vedotin for treating solid cancers; HuMax-AXL-ADC for solid cancers; Teprotumumab for the treatment of Graves' orbitopathy; AMG 714 for celiac disease; ADCT-301 (HuMax-TAC-ADC) to treat lymphoma and acute myeloid leukemia (AML) or acute lymphoblastic leukemia; JNJ-61186372 for non-small-cell lung cancer; and NJ-63709178 for the treatment of AML. In addition, it has approximately 20 active pre-clinical programs, including naked, bispecific, and immune effector function enhanced antibodies. The company was founded in 1999 and is based in Copenhagen, Denmark.

Receive GNMSF News and Ratings via Email

Sign-up to receive the latest news and ratings for GNMSF and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorMedical
SymbolOTCMKTS:GNMSF
CUSIPN/A
Phone45-7020-2728

Debt

Debt-to-Equity RatioN/A
Current Ratio13.04%
Quick Ratio13.04%

Price-To-Earnings

Trailing P/E Ratio63.84
Forward P/E Ratio67.59
P/E GrowthN/A

Sales & Book Value

Annual Sales$269.88 million
Price / Sales40.00
Cash Flow$2.79 per share
Price / Cash63.13
Book Value$11.89 per share
Price / Book14.84

Profitability

Trailing EPSN/A
Net Income$176.39 million
Net Margins50.29%
Return on Equity21.78%
Return on Assets20.02%

Miscellaneous

Employees205
Outstanding Shares61,190,000

Genmab As (OTCMKTS:GNMSF) Frequently Asked Questions

What is Genmab As' stock symbol?

Genmab As trades on the OTCMKTS under the ticker symbol "GNMSF."

How were Genmab As' earnings last quarter?

Genmab As (OTCMKTS:GNMSF) posted its quarterly earnings results on Wednesday, November, 5th. The company reported $0.47 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.45 by $0.02. The company had revenue of $45.65 million for the quarter, compared to analyst estimates of $53.94 million. Genmab As had a return on equity of 21.78% and a net margin of 50.29%. View Genmab As' Earnings History.

When will Genmab As make its next earnings announcement?

Genmab As is scheduled to release their next quarterly earnings announcement on Tuesday, March, 27th 2018. View Earnings Estimates for Genmab As.

Who are some of Genmab As' key competitors?

How do I buy Genmab As stock?

Shares of Genmab As can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Genmab As' stock price today?

One share of Genmab As stock can currently be purchased for approximately $176.40.

How big of a company is Genmab As?

Genmab As has a market capitalization of $11.29 billion and generates $269.88 million in revenue each year. Genmab As employs 205 workers across the globe.

How can I contact Genmab As?

Genmab As' mailing address is BREDGADE 34E, COPENHAGEN G7, . The company can be reached via phone at 45-7020-2728 or via email at [email protected]


MarketBeat Community Rating for Genmab As (GNMSF)

Community Ranking:  1.8 out of 5 (star)
Outperform Votes:  55 (Vote Outperform)
Underperform Votes:  101 (Vote Underperform)
Total Votes:  156
MarketBeat's community ratings are surveys of what our community members think about Genmab As and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Genmab As (OTCMKTS:GNMSF) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldBuy
Consensus Rating Score: 2.002.002.002.50
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: N/AN/AN/AN/A
Price Target Upside: N/AN/AN/AN/A

Genmab As (OTCMKTS:GNMSF) Consensus Price Target History

Price Target History for Genmab As (OTCMKTS:GNMSF)

Genmab As (OTCMKTS:GNMSF) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
10/6/2017JPMorgan Chase & Co.DowngradeOverweight -> NeutralView Rating Details
4/4/2017Deutsche BankDowngradeBuy -> HoldView Rating Details
(Data available from 2/21/2016 forward)

Earnings

Genmab As (OTCMKTS:GNMSF) Earnings History and Estimates Chart

Earnings by Quarter for Genmab As (OTCMKTS:GNMSF)

Genmab As (OTCMKTS GNMSF) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/27/2018        
5/10/2017Q1 2017$0.04$35.19 million$35.93 millionViewN/AView Earnings Details
3/28/2017Q4 2016$1.98$134.64 millionViewN/AView Earnings Details
11/2/2016Q3 2016$0.46$54.70 millionViewN/AView Earnings Details
8/9/2016Q2 2016$0.24$0.41$49.68 million$53.72 millionViewN/AView Earnings Details
5/10/2016Q1 2016($0.25)($0.03)$10.31 million$25.15 millionViewN/AView Earnings Details
2/17/2016Q4 2015$0.95$84.32 millionViewN/AView Earnings Details
11/3/2015Q3 2015$0.34$41.41 millionViewN/AView Earnings Details
8/11/2015Q2 2015$0.44$0.04$47.57 million$25.76 millionViewN/AView Earnings Details
5/12/2015Q1 2015$0.55$16.19 millionViewN/AView Earnings Details
11/5/2014Q3 2014$0.45$0.47$53.94 million$45.65 millionViewN/AView Earnings Details
8/13/2014Q2 2014($0.06)($0.08)$26.02 million$20.79 millionViewN/AView Earnings Details
5/7/2014Q1 2014($0.09)$0.33$21.18 million$46.08 millionViewN/AView Earnings Details
11/6/2013Q3 2013($0.01)$0.02$25.52 million$27.12 millionViewN/AView Earnings Details
8/14/2013Q2 2013($0.01)($0.09)$24.45 million$24.54 millionViewN/AView Earnings Details
5/7/2013Q1 2013$0.11$28.09 millionViewN/AView Earnings Details
11/7/2012Q3 2012($0.17)($0.17)ViewN/AView Earnings Details
8/15/2012Q2 2012($0.32)$0.03ViewN/AView Earnings Details
5/15/2012Q1 2012($0.25)($0.23)ViewN/AView Earnings Details
11/2/2011Q3 2011($0.04)ViewN/AView Earnings Details
5/11/2011Q1 2011($0.16)($0.43)ViewN/AView Earnings Details
11/22/2010Q3 2010$0.48ViewN/AView Earnings Details
8/17/2010Q2 2010($0.46)($0.30)ViewN/AView Earnings Details
5/11/2010Q1 2010($0.77)($0.47)ViewN/AView Earnings Details
11/10/2009Q3 2009($1.17)($0.44)ViewN/AView Earnings Details
8/18/2009Q2 2009($1.18)($0.54)ViewN/AView Earnings Details
5/12/2009Q1 2009($1.04)($0.79)ViewN/AView Earnings Details
8/27/2008Q2 2008($1.38)ViewN/AView Earnings Details
5/28/2008Q1 2008($0.95)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Genmab As (OTCMKTS:GNMSF) Earnings Estimates

Current Year EPS Consensus Estimate: $2.61 EPS
Next Year EPS Consensus Estimate: $4.27 EPS

Dividends

Dividend History for Genmab As (OTCMKTS:GNMSF)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Genmab As (OTCMKTS GNMSF)

No insider trades for this company have been tracked by MarketBeat.com

Headlines

Genmab As (OTCMKTS GNMSF) News Headlines

Source:
DateHeadline
Q4 2017 Earnings Forecast for Genmab As Issued By Jefferies Group (GNMSF)Q4 2017 Earnings Forecast for Genmab As Issued By Jefferies Group (GNMSF)
www.americanbankingnews.com - February 7 at 8:18 AM
Genmab Announces 2017 Net Sales Figures for DARZALEX® (Daratumumab)Genmab Announces 2017 Net Sales Figures for DARZALEX® (Daratumumab)
finance.yahoo.com - January 23 at 8:50 AM
U.S. FDA Grants Priority Review for Daratumumab in Front Line Multiple MyelomaU.S. FDA Grants Priority Review for Daratumumab in Front Line Multiple Myeloma
finance.yahoo.com - January 19 at 5:33 PM
Genmab As (GNMSF) Rating Lowered to Sell at Zacks Investment ResearchGenmab As (GNMSF) Rating Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - January 9 at 11:54 PM
Analysts Issue Forecasts for Genmab As FY2018 Earnings (GNMSF)Analysts Issue Forecasts for Genmab As' FY2018 Earnings (GNMSF)
www.americanbankingnews.com - January 8 at 12:06 PM
ETFs with exposure to Genmab A/S : December 27, 2017ETFs with exposure to Genmab A/S : December 27, 2017
finance.yahoo.com - December 28 at 6:10 AM
Genmab A/S :GNMSF-US: Earnings Analysis: Q3, 2017 By the Numbers : December 26, 2017Genmab A/S :GNMSF-US: Earnings Analysis: Q3, 2017 By the Numbers : December 26, 2017
finance.yahoo.com - December 26 at 9:16 AM
After Soaring 3,000% in 5 Years, Genmab Tests Stock-Market HabitAfter Soaring 3,000% in 5 Years, Genmab Tests Stock-Market Habit
finance.yahoo.com - December 18 at 5:04 PM
Genmab Achieves USD 20 Million Milestone in Daratumumab Collaboration with Janssen and Updates Financial GuidanceGenmab Achieves USD 20 Million Milestone in Daratumumab Collaboration with Janssen and Updates Financial Guidance
finance.yahoo.com - November 29 at 5:24 PM
Genmab A/S (GNMSF) Downgraded by Zacks Investment ResearchGenmab A/S (GNMSF) Downgraded by Zacks Investment Research
www.americanbankingnews.com - November 26 at 3:34 PM
Genmab Announces European Regulatory Submission for Daratumumab in Front Line Multiple MyelomaGenmab Announces European Regulatory Submission for Daratumumab in Front Line Multiple Myeloma
finance.yahoo.com - November 21 at 7:08 PM
Genmab Announces Submission of Supplemental Biologics License Application to FDA for Daratumumab in Front Line Multiple MyelomaGenmab Announces Submission of Supplemental Biologics License Application to FDA for Daratumumab in Front Line Multiple Myeloma
finance.yahoo.com - November 21 at 7:08 PM
Genmab A/S breached its 50 day moving average in a Bullish Manner : GNMSF-US : November 16, 2017Genmab A/S breached its 50 day moving average in a Bullish Manner : GNMSF-US : November 16, 2017
finance.yahoo.com - November 16 at 2:48 PM
Major Shareholder AnnouncementMajor Shareholder Announcement
finance.yahoo.com - November 11 at 7:23 AM
Genmab Announces Financial Results for the First Nine Months of 2017Genmab Announces Financial Results for the First Nine Months of 2017
finance.yahoo.com - November 9 at 6:12 AM
Genmab A/S – Value Analysis (US OTC:GNMSF) : November 1, 2017Genmab A/S – Value Analysis (US OTC:GNMSF) : November 1, 2017
finance.yahoo.com - November 1 at 9:07 PM
Genmab A/S breached its 50 day moving average in a Bullish Manner : GNMSF-US : October 31, 2017Genmab A/S breached its 50 day moving average in a Bullish Manner : GNMSF-US : October 31, 2017
finance.yahoo.com - October 31 at 8:33 PM
Genmab Announces Additional Information Concerning Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2017Genmab Announces Additional Information Concerning Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2017
finance.yahoo.com - October 25 at 2:33 AM
Genmab A/S breached its 50 day moving average in a Bearish Manner : GNMSF-US : October 18, 2017Genmab A/S breached its 50 day moving average in a Bearish Manner : GNMSF-US : October 18, 2017
finance.yahoo.com - October 19 at 12:08 AM
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2017Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2017
finance.yahoo.com - October 17 at 7:52 PM
Seattle Genetics initiates mid-stage of tisotumab vedotin in cervical cancer, positive results may support registrationSeattle Genetics initiates mid-stage of tisotumab vedotin in cervical cancer, positive results may support registration
seekingalpha.com - October 10 at 9:53 PM
Genmab and Seattle Genetics to Initiate New Study of Novel Antibody-Drug Conjugate Tisotumab Vedotin in Cervical CancerGenmab and Seattle Genetics to Initiate New Study of Novel Antibody-Drug Conjugate Tisotumab Vedotin in Cervical Cancer
finance.yahoo.com - October 10 at 4:49 PM
Genmab A/S (GNMSF) Rating Lowered to Neutral at J P Morgan Chase & CoGenmab A/S (GNMSF) Rating Lowered to Neutral at J P Morgan Chase & Co
www.americanbankingnews.com - October 7 at 3:36 PM
Genmab Announces Approval of DARZALEX® (daratumumab) for Relapsed or Refractory Multiple Myeloma in JapanGenmab Announces Approval of DARZALEX® (daratumumab) for Relapsed or Refractory Multiple Myeloma in Japan
finance.yahoo.com - October 2 at 1:56 PM
Genmab A/S breached its 50 day moving average in a Bearish Manner : GNMSF-US : September 18, 2017Genmab A/S breached its 50 day moving average in a Bearish Manner : GNMSF-US : September 18, 2017
finance.yahoo.com - September 18 at 6:43 PM
Genmab A/S :GNMSF-US: Earnings Analysis: Q2, 2017 By the Numbers : September 12, 2017Genmab A/S :GNMSF-US: Earnings Analysis: Q2, 2017 By the Numbers : September 12, 2017
finance.yahoo.com - September 12 at 7:58 PM
Seattle Genetics and Genmab team up to develop ADC tisotumab vedotinSeattle Genetics and Genmab team up to develop ADC tisotumab vedotin
seekingalpha.com - August 30 at 9:33 PM
J&Js Darzalex extends progression-free survival in late-state multiple myeloma study over Velcade/MP aloneJ&J's Darzalex extends progression-free survival in late-state multiple myeloma study over Velcade/MP alone
seekingalpha.com - August 25 at 6:20 AM
Genmab Announces Positive Topline Results in Phase III ALCYONE Study of Daratumumab in Front Line Multiple MyelomaGenmab Announces Positive Topline Results in Phase III ALCYONE Study of Daratumumab in Front Line Multiple Myeloma
finance.yahoo.com - August 25 at 6:20 AM
Genmab A/S – Value Analysis (US OTC:GNMSF) : August 21, 2017Genmab A/S – Value Analysis (US OTC:GNMSF) : August 21, 2017
finance.yahoo.com - August 23 at 7:38 AM
Genmab A/S breached its 50 day moving average in a Bearish Manner : GNMSF-US : August 21, 2017Genmab A/S breached its 50 day moving average in a Bearish Manner : GNMSF-US : August 21, 2017
finance.yahoo.com - August 21 at 6:32 PM
Genmab A/S breached its 50 day moving average in a Bearish Manner : GNMSF-US : August 10, 2017Genmab A/S breached its 50 day moving average in a Bearish Manner : GNMSF-US : August 10, 2017
finance.yahoo.com - August 11 at 12:47 AM
Genmabs (GNMSF) CEO Jan van de Winkel on Q2 2017 Results - Earnings Call TranscriptGenmab's (GNMSF) CEO Jan van de Winkel on Q2 2017 Results - Earnings Call Transcript
seekingalpha.com - August 9 at 7:18 PM
Genmab Announces Financial Results for the First Half of 2017Genmab Announces Financial Results for the First Half of 2017
finance.yahoo.com - August 9 at 7:18 PM
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2017Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2017
finance.yahoo.com - July 18 at 8:51 PM
Genmabs (GNMSF) CEO Jan van de Winkel on Q1 2017 Results - Earnings Call TranscriptGenmab's (GNMSF) CEO Jan van de Winkel on Q1 2017 Results - Earnings Call Transcript
www.msn.com - May 11 at 3:41 AM
Genmabs (GNMSF) CEO Jan van de Winkel on Q4 2016 Results - Earnings Call TranscriptGenmab's (GNMSF) CEO Jan van de Winkel on Q4 2016 Results - Earnings Call Transcript
seekingalpha.com - February 22 at 10:48 PM
Genmab Lifts FY16 View For Revenue, Operating Income - Quick Facts - NasdaqGenmab Lifts FY16 View For Revenue, Operating Income - Quick Facts - Nasdaq
www.nasdaq.com - February 8 at 4:46 AM
Genmab Lifts FY16 View For Revenue, Operating Income - Quick FactsGenmab Lifts FY16 View For Revenue, Operating Income - Quick Facts
www.rttnews.com - February 6 at 5:33 PM
Genmab Says 2016 Sales Of Darzalex Totaled $572 Mln - Quick Facts - NasdaqGenmab Says 2016 Sales Of Darzalex Totaled $572 Mln - Quick Facts - Nasdaq
www.nasdaq.com - January 24 at 11:12 PM
Genmab Says 2016 Sales Of Darzalex Totaled $572 Mln - Quick FactsGenmab Says 2016 Sales Of Darzalex Totaled $572 Mln - Quick Facts
www.rttnews.com - January 24 at 6:10 PM
Genmab A/S breached its 50 day moving average in a Bullish Manner : GNMSF-US : January 6, 2017Genmab A/S breached its 50 day moving average in a Bullish Manner : GNMSF-US : January 6, 2017
us.rd.yahoo.com - January 6 at 6:03 PM
Janssen files Darzalex marketing application in Japan for multiple myeloma; $10M milestone due Genmab - Seeking AlphaJanssen files Darzalex marketing application in Japan for multiple myeloma; $10M milestone due Genmab - Seeking Alpha
seekingalpha.com - December 21 at 6:24 PM
Genmab To Get $10 Mln Milestone Payment From Janssen; Lifts FY16 Forecast - NasdaqGenmab To Get $10 Mln Milestone Payment From Janssen; Lifts FY16 Forecast - Nasdaq
www.nasdaq.com - December 21 at 6:24 PM
Janssen files Darzalex marketing application in Japan for multiple myeloma; $10M milestone due GenmabJanssen files Darzalex marketing application in Japan for multiple myeloma; $10M milestone due Genmab
seekingalpha.com - December 20 at 10:26 PM
Genmab To Get $10 Mln Milestone Payment From Janssen; Lifts FY16 ForecastGenmab To Get $10 Mln Milestone Payment From Janssen; Lifts FY16 Forecast
www.rttnews.com - December 20 at 10:41 AM
Genmab A/S (GNMSF): Strong Industry, Solid Earnings Estimate Revisions - NasdaqGenmab A/S (GNMSF): Strong Industry, Solid Earnings Estimate Revisions - Nasdaq
www.nasdaq.com - December 2 at 8:27 AM
Genmab A/S (GNMSF): Strong Industry, Solid Earnings Estimate RevisionsGenmab A/S (GNMSF): Strong Industry, Solid Earnings Estimate Revisions
us.rd.yahoo.com - December 1 at 10:37 PM
J&J Immunotherapy Darzalex OKd for Label Expansion by FDAJ&J Immunotherapy Darzalex OK'd for Label Expansion by FDA
www.zacks.com - November 22 at 8:45 AM
ACOR Fails To Walk The Talk, SNY Gets FDA Nod, New Use For Genmabs Old DrugACOR Fails To Walk The Talk, SNY Gets FDA Nod, New Use For Genmab''s Old Drug
www.nasdaq.com - November 22 at 8:45 AM

SEC Filings

Genmab As (OTCMKTS:GNMSF) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Financials are not available for this stock.

Chart

Genmab As (OTCMKTS GNMSF) Stock Chart for Wednesday, February, 21, 2018

Loading chart…

This page was last updated on 2/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.